Reminder: Expert Access: Drug Reimbursement Call with Payor Expert for Key Reads to Our Coverage (MDGL, IONS, VRTX, ALNY, BBIO)

Research evidence excerpt

Reminder: Expert Access: Drug Reimbursement Call with Payor Expert for Key Reads to Our Coverage (MDGL, IONS, VRTX, ALNY, BBIO)

•• Rezdiffra coverage and positioning with respect to GLP1s: Contracting,

reimbursement expectations, and positioning vs. GLP1s, including potential and

feasibility for step edits and concurrent use considerations.

•• Tryngolza utilization management considerations: Patient identification, estimated

patients eligible, step edits, documentation requirement based on prior standard-of-

care use and adherence and tolerance.

•• Journavx coverage in different neuropathic pains: Prior authorization requirements

and quantity limit for acute pain, coverage considerations for diabetic neuropathy if

data positive, and outlook for Journavx coverage in other neuropathic pains.

•• ATTR-CM reimbursement dynamics and sequencing: Coverage and sequencing across

stabilizers and silencers, potential coverage for stabilizer+silencer combo, prior

authorization criteria, generic tafamidis impacts and Part B vs. Part D post part D

redesign.

Relevant Research

MDGL 5/7/2026 - 1Q model update and color from mgmt from our hosted Q&A: We have

high conviction in shares

MDGL 5/6/2026 - 1Q Take: Rezdiffra beat despite 1Q headwinds, a solid Q

MDGL 3/31/2026 - 1Q Preview: Expect seasonality for Rezdiffra in 1Q but a strong '26

beyond

MDGL 2/20/2026 - Reiterate conviction in Rezdiffra

MDGL 2/19/2026 - Buying opportunity on solid fundamentals

MDGL 2/19/2026 - MDGL: Solid 4Q, patient adds accelerating

MDGL 2/11/2026 - Welcome to the Family, Madrigal

US Biotech 5/28/2026 - Cardiologist call takeaways: How will CARDIO-TTRansform move

IONS, AZN, ALNY, and BBIO?

US Biotech 5/27/2026 - How will CARDIO-TTRansform change the ATTR treatment

paradigm?